ArticleScientific reports2025
Identification of STAT3 signaling as a shared pathogenic signature in systemic lupus erythematosus, chronic obstructive pulmonary disease, and asthma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While patients with systemic lupus erythematosus (SLE) have a higher risk of developing chronic obstructive pulmonary disease (COPD) and asthma, the underlying mechanisms have yet to be elucidated. To this end, by integrating transcriptomic data obtained from blood specimens for each disorder, this study made an effort to investigate shared pathogenic signatures in these three disorders. After identification of shared differentially expressed genes (DEGs), their protein interactions (PPIs) were mapped using a high confidence threshold (0.7). Construction of the networks led to the identification of STAT3 as the central hub gene. Functional enrichment analysis of the shared PPI network of SLE, COPD, and asthma revealed involvement of the shared DEGs in the activation of innate immunity in conjunction with the dysregulation of adaptive immunity, specifically the differentiation of Th1, Th2, and Th17 cells. Moreover, Gene Ontology (GO) analysis highlighted a substantial imbalance between kinase and phosphatase. These observations suggest the STAT3 signaling pathway not only as a pathogenic link between SLE, COPD, and asthma but also as a potential therapeutic target for patients diagnosed with a combination of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.